Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MTEM

MTEM - Molecular Templates Inc Stock Price, Fair Value and News

00
Market Closed

Price Targets

MTEM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MTEM Price Action

Trailing 12 Months

-100%

MTEM RSI Chart

MTEM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MTEM Valuation

MTEM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

MTEM Fundamentals

MTEM Revenue

MTEM Earnings

MTEM Profitability

MTEM Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202431.8M25.5M00
202347.9M50.3M52.9M57.3M
202244.0M33.2M35.1M19.8M
202117.9M26.1M24.2M38.7M
202019.4M20.9M21.5M18.8M
201919.8M23.9M20.8M22.3M
20182.0M3.3M9.4M13.3M
20172.3M2.6M3.0M3.4M
20160039.4M1.9M
201514.7M14.7M14.7M76.9M
201413.3M13.8M14.3M14.7M
20138.5M9.9M11.3M12.5M
20121.3M2.6M3.9M5.9M
201100062.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Molecular Templates Inc

MTEM
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
 CEO
 WEBSITEmtem.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES111

Molecular Templates Inc Frequently Asked Questions

MTEM is the stock ticker symbol of Molecular Templates Inc. Every public company that trades on a stock exchange gets a ticker symbol.

You can check MTEM's fair value in chart for subscribers.

The fair value guage provides a quick view whether MTEM is over valued or under valued. Whether Molecular Templates Inc is cheap or expensive depends on the assumptions which impact Molecular Templates Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MTEM.

In the past 10 years, Molecular Templates Inc has provided -1 (multiply by 100 for percentage) rate of return.